HCPCS code J7186 – Factor VIII/von Willebrand factor complex (human), per factor VIII IU

Key takeaways

J7186 reports the plasma-derived factor VIII/von Willebrand factor complex (human), billed per factor VIII IU, and Alphanate is the product it describes.

It is not a recombinant factor VIII code, so Advate, Kogenate FS, Recombinate, Nuwiq, Jivi and Esperoct all bill under other codes.

Supporting diagnoses are hemophilia A (D66) and von Willebrand disease, which now needs a specific D68.0- subcode.

Bill one unit per factor VIII IU actually infused, using the potency printed on each vial rather than the nominal vial size.

Most clean J7186 claims come down to three checks: the right code for the product, the matching NDC and the actual IU infused.

What HCPCS code J7186 covers and how it’s counted

HCPCS code J7186 describes an injection of antihemophilic factor VIII/von Willebrand factor complex (human), billed per factor VIII IU.

It’s a plasma-derived concentrate that carries both clotting proteins, factor VIII (FVIII) and von Willebrand factor (VWF). Alphanate from Grifols is the product billed under it, for hemophilia A and for procedures in von Willebrand disease.

The unit is counted in factor VIII international units, even when the product is given for von Willebrand disease. That detail sets it apart from J7187 and J7183, which count VWF units instead.

Only Alphanate bills under J7186

J7186 is a product-specific code in practice. Alphanate is the FVIII/VWF complex (human) that payer policies and the CMS NDC-HCPCS crosswalk map to it. Every other factor VIII or VWF product has a code of its own.

• Covered: Alphanate, a plasma-derived antihemophilic factor/von Willebrand factor complex (human) made by Grifols.
• Humate-P (CSL Behring): bills under J7187, which is counted per IU of VWF:RCo, not per factor VIII IU.
• Wilate (Octapharma): bills under J7183, also counted per IU of VWF:RCo.
• Plasma-derived factor VIII without a VWF claim: bills under J7190, factor VIII (antihemophilic factor, human), per IU.
• Recombinant factor VIII: never J7186. Advate, Kogenate FS, Helixate FS and Recombinate bill under J7192. Nuwiq, Jivi and Esperoct have dedicated codes (J7209, J7208 and J7204).

Product portfolios and code assignments change, so check the NDC against the current CMS crosswalk before you bill. If the vial in hand turns out to be recombinant, our J7192 page explains how those products bill.

J7186 treats hemophilia A and von Willebrand disease

Hemophilia A is an inherited deficiency of factor VIII, coded as D66 (hereditary factor VIII deficiency). Alphanate is labeled to prevent and control bleeding in these patients, including around surgery.

Von Willebrand disease (VWD) is the most common inherited bleeding disorder. Low or faulty VWF impairs platelet adhesion and also shortens the life of factor VIII in circulation. Alphanate is labeled for surgery and invasive procedures in VWD patients when desmopressin (DDAVP) is ineffective or contraindicated.

One label limit matters for coding review. Alphanate is not indicated for patients with severe (type 3) VWD who are undergoing major surgery. A claim pairing J7186 with type 3 VWD and a major surgical procedure deserves a second look before it goes out.

Documentation should show the treatment reason (prophylaxis, a bleeding episode or a procedure), the weight-based dose and the factor VIII IU infused. Hemophilia treatment centers (HTCs) often coordinate this care and may hold their own payer arrangements.

Diagnosis codes that support a J7186 claim

Hemophilia A is reported with D66. Von Willebrand disease needs the subtype the chart supports, because D68.0 has been a category heading rather than a billable code since October 1, 2022.

D68.311 (acquired hemophilia) and D68.312 (antiphospholipid antibody with hemorrhagic disorder) don’t support J7186. Acquired inhibitors call for other treatments, so leave those codes off a J7186 claim.

Bill J7186 by the IU printed on each vial

Bill one unit of J7186 for each factor VIII IU infused. Alphanate vials are labeled with their actual FVIII potency, which varies around the nominal size, so add up the IU printed on each vial used.

For example, two vials labeled 1,032 IU and 1,018 IU, both fully infused, give 2,050 units on the claim line. Billing 2,000 because the vials are sold as 1,000 IU each understates the dose.

The administration goes on its own claim line. When your staff give the injection, that is usually 96374 for an IV push. Check the payer’s rules for home infusion before you add one.

Read the NDC from the carton in hand

Every Part B drug claim line needs the 11-digit NDC of the product given. Alphanate carries the Grifols labeler code 68516, with a separate NDC for each potency range.

Grifols has changed Alphanate presentations over the years, and older NDCs drop out of the crosswalk. Read the NDC from the carton in hand rather than a saved list.

Medicare pays J7186 at ASP plus 6%, plus a furnishing fee

Medicare Part B pays J7186 at 106% of the average sales price (ASP+6%). CMS updates the payment limit quarterly, and the rate in force on the date of service applies.

Clotting factors also earn a separate blood clotting factor furnishing fee, paid per IU on top of the drug payment. CMS publishes the fee each year, so check it alongside the quarterly ASP file.

• Where to find current rates: download the quarter’s Medicare Part B payment limit file from the CMS ASP pricing files page.
• Medicaid: fee-for-service rates and authorization rules vary by state, and managed care plans set their own. Never apply one state’s rate to another.
• Coordination of benefits: bill the primary payer first, then send the secondary claim with the primary remittance attached.

Most plans want prior authorization for J7186

Most commercial and Medicaid managed care plans require prior authorization for J7186. Policies such as Centene’s factor VIII/VWF complex policy group it with Humate-P and Wilate.

Original Medicare doesn’t generally require prior authorization for Part B clotting factors. Still, check your Medicare Administrative Contractor’s local policies, and expect Medicare Advantage plans to set their own rules.

Authorization requests usually need the confirmed diagnosis with factor VIII or VWF lab results and the treatment plan. For VWD, plans often ask for evidence that desmopressin is ineffective or contraindicated. Our walkthrough of the prior authorization process covers how a request moves from submission to decision.

• Authorization periods: approvals run for a set period. Track expiry dates and request renewal before the approval lapses.
• Quantity limits: some plans cap the total IU per period. File an amendment before the dose goes past the approved amount.
• HTC arrangements: confirm whether an HTC’s authorization also covers claims from an affiliated infusion service.

Three questions separate J7186 from its neighbors

Factor VIII and VWF products split across several codes, and three questions settle which one applies. Is the factor recombinant, does the product carry a VWF claim, and which complex is it? The diagram walks through them in order.

The unit column is where most errors hide. Moving a patient from Humate-P to Alphanate changes both the code and the unit basis, so recalculate the units rather than copying them. The J7187 page shows how the VWF:RCo count works on the other side of that switch.

Four denials that hit J7186 claims, and their fixes

J7186 claims tend to come back for one of four reasons, and each has a straightforward fix. The denial codes reference covers the full CARC list.

Appeal deadlines vary by payer and plan type. Note each deadline in your billing workflow on the day the denial arrives.

Mistakes that send J7186 claims back

• Billing the nominal vial size. Two 1,000 IU vials labeled 1,032 and 1,018 IU are 2,050 units, not 2,000.
• Copying units after a product switch. Humate-P counts VWF:RCo units, so its totals never carry over to Alphanate.
• Reporting D68.0 on its own. It stopped being billable in 2022, so the claim needs the VWD subtype.
• Putting a recombinant product on J7186. Advate or Kogenate FS on this code fails the NDC check before anyone reads the chart.

Before you submit: A J7186 documentation checklist

Use this checklist before you submit. The medical billing fundamentals guide covers wider claim workflows.

• Diagnosis of hemophilia A (D66) or a specific VWD subtype (D68.0-), with supporting lab results
• For VWD, a note on why desmopressin is ineffective or contraindicated
• Order naming Alphanate, the dose in factor VIII IU and the treatment reason
• Administration record with the IU printed on each vial infused, plus lot numbers
• 11-digit NDC with the N4 qualifier on the claim line
• Prior authorization number in date, with approved IU covering the dose
• POS code that matches where the injection was given
• Ordering and rendering provider NPIs
• Administration code when staff gave the injection
• Secondary coverage details where they apply

How Pabau keeps J7186 claims and remittances together

Factor claims carry high values, so a returned claim ties up a lot of money. Many practices still key clotting factor claims by hand and chase remittances across separate portals.

Pabau, the practice management platform we build, keeps the order, the infusion record and the claim on one patient record. Its claims management software sends US claims through Claim.MD, covering CMS-1500/837P claims, eligibility checks and ERA remittances.

Eligibility checks before the visit flag coverage problems early. ERA remittances then post against the original claim, so you can see when a payment falls short of the expected rate.

Keep factor claims and remittances in one place

Pabau supports US claims through Claim.MD, with CMS-1500/837P claims, eligibility checks and ERA remittances linked to the patient record.

Book a demo

Conclusion

Treat J7186 as the Alphanate code and the rest of the claim falls into place. The product sets the code, the vial labels set the units and the carton sets the NDC.

The cost is a little more recording at the infusion chair, with each vial’s potency and lot noted as it’s used. That record is what stops a 2,050-unit dose going out as 2,000, or a Humate-P switch landing on the wrong code.

Book a demo to see how Pabau keeps factor orders, infusion records and Claim.MD claims on one patient record.

Continue your research

Need to understand how clearinghouse claim submission works? Medical claims clearinghouse guide explains how electronic claims are validated and routed to payers.

Seeing recurring denial patterns across your drug claims? Denial management in healthcare covers root-cause analysis and appeal strategy for specialty drug J-codes.

Want to understand how ERA remittance data maps back to claims? Electronic remittance advice (ERA) explained covers 835 transaction reading and payment posting workflows.

Need a request form for factor concentrates? Medical prior authorization form gives you a template for the diagnosis, treatment plan and supporting evidence a plan asks for.

Frequently asked questions